COVID-19 outbreak update: AIS2020 Congress has been postponed to November 23-24, 2020.
In regard to the current situation due to the COVID-19 epidemic and after careful consideration, the organization committee (LabEx MAbImprove and MabDesign), with the approval of scientific advisory committee, has decided to postpone this year’s AIS Congress to the 23rd and the 24th of November 2020, with the same venue at the Congress Center Corum of Montpellier, France.
We are committed to offer all speakers, sponsors, exhibitors, partners and participants the best conditions to attend and exchange during this event. This commitment has thus driven the hard decision to postpone the AIS Congress to November 23rd-24th. We are confident that the current crisis will be resolved by then and that all of us will fully benefit from the event.
We are looking forward to welcoming you in Montpellier in November, in the meantime please stay safe,
The organizing committee
The scientific committee
Dear colleague,
We are proud to announce the 8th Antibody Industrial Symposium 2020 (AIS2020) that will be held the on 22nd and 23rd of June 2020 in Montpellier, France. This international congress is jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign. It is part of the series of Industrial Symposia organized by MAbImprove since 2013, whose previous topics were: Antibodies Biosimilars, MAbDosing, MAbDelivery, Current & Next Generation Antibody Formats, Antibody Drug Conjugates, Targets for Mabs, and Harnessing the Immune System with Abs.
The AIS2020 is the ideal conference for scientists, industrials, physicians and policy makers to exchange about therapeutic antibodies.
The Scientific committee has set-up an exciting program around this year theme: “Multispecific Abs, Ab-like molecules and adoptive cell therapy for fighting diseases”, with keynote lectures, pitch talks around new creative projects, and industrial talks from big pharmaceutical companies.
The next frontier of Ab-based therapeutics for fighting diseases is the production and application of higher-order multispecific Abs or Ab-like molecules, as well as novel cytokine-based biologics or engineered artificial chimeric antigen receptors (CARs). Indeed multispecific Abs and next-generation immunocytokines provide promising platform for the development of novel therapeutic concepts that could facilitate the generation of safer, more effective pharmaceuticals. Re-directing immune cells with engineered CARs is an exciting approach for efficient adoptive cell therapy. AIS2020 will cover the multifaceted mechanisms induced by novel multimer derivatives, cytokine-based products and CARs in different pathophysiological situations. It will also focus on CMC developability (Chemistry Manufacturing Control) and the early clinical development.
The program will allow opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering.
The Symposium will take place at the “Corum” conference center in Montpellier, close to the train station, providing easy transport connection and accommodations close to the venue.
Visit the website: aiscongress.com
Looking forward to welcoming you to the 8th Antibody Industrial Symposium 2020 in Montpellier!
Best regards,
The Organizing Committee – LabEx MabImprove and MabDesign
The Scientific Committee
